clinical trial · NCT04119557
A Study of LY3471851 in Participants With Psoriasis
PsoriasisPlaceboLY3471851
brief summary
The main purpose of this study is to learn more about the safety of LY3471851 when given by injection just under the skin to participants with psoriasis. The study will last up to 48 weeks and may include up to 23 visits to the study center.
started
Nov 26, 2019
primary completion
Jul 21, 2021
completion
Jul 21, 2021
last updated
Feb 20, 2024
official title
A Phase 1, Double-Blind, Randomized, Placebo-Controlled, Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous LY3471851 in Patients With Psoriasis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol